Mylan introduces Mylan-Nifedipine Extended Release 30 mg - a first in Canada

TORONTO, May 5 /CNW Telbec/ - Mylan Pharmaceuticals ULC today announces it has launched Mylan-Nifedipine Extended Release tablets in 30 mg strength. Mylan is the only company in Canada to offer this generic alternative to Adalat(R) XL(R). Previously available in 60 mg tablets, the addition of the 30 mg is another example of how generic manufacturers offer patients greater access to high quality products. Mylan-Nifedipine Extended Release is an important antihypertensive for patients suffering from angina and/or hypertension.

Health Canada has declared Mylan-Nifedipine Extended Release tablets bioequivalent to Adalat(R) XL(R). "We take pride in being the first and only company to offer a generic alternative to Adalat(R) XL(R) in Canada," said Dick Guest, President and CEO of Mylan in Canada. "The launch of this unique and difficult to manufacture tablet demonstrates our dedication to providing quality, more affordable medicines to the Canadian market."

Total sales for Adalat(R) XL(R) 30 mg in Canada were approximately $81 million ($CDN) for the 12 months ending December 31, 2009.

The new medicine continues a long line of Mylan products carefully made to treat angina and/or hypertension including Mylan-Amlodipine, Mylan-Ramipril and Mylan-Lisinopril.

For more information, please visit www.mylan.ca/nifedipine.

Mylan Pharmaceuticals ULC is the Canadian subsidiary of U.S.-based Mylan Inc. (Mylan), which ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. Mylan maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Pharmaceuticals ULC

For further information: For further information: Kathleen Stelmach, Torchia Communications, (416) 341-9929, ext. 227, kathleen@torchiacom.com

Organization Profile

Mylan Pharmaceuticals ULC

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890